Irbesartan Tolife

Irbesartan, the active ingredient in Irbesartan Tolife, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is prescribed to lower high blood pressure, protect kidney function in adults with diabetic nephropathy, and reduce cardiovascular risk in this population.

GNH USA supplies Irbesartan Tolife as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across multiple regions. We maintain stringent quality controls and provide technical support to our partners.

Irbesartan is an Angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system. - Hypertension: lowers elevated blood pressure to target ranges. - Diabetic nephropathy: slows decline of renal function in patients with type 2 diabetes. - Proteinuria: reduces urinary protein excretion associated with renal disease.

Irbesartan may cause a range of adverse reactions, which are generally classified as common or serious.

Common Side Effects: - Dizziness - Headache - Fatigue - Nausea

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or airway. - Severe hypotension: marked drop in blood pressure causing faintness. - Hyperkalemia: elevated blood potassium that can affect heart rhythm. - Acute kidney injury: sudden decline in renal function.

When prescribing Irbesartan, clinicians should observe several safety measures. - Blood pressure monitoring: check regularly to avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium: monitor for hyperkalemia, especially with potassium‑sparing agents. - Pregnancy: avoid use during the second and third trimesters due to potential fetal harm. - Drug interactions: review concomitant medications that affect the renin‑angiotensin system. - Store at room temperature: keep in original packaging, protect from moisture and heat.

Irbesartan interacts with several medicines; the significance varies.

Major Interactions (Avoid): - Concomitant use with ACE inhibitors or aliskiren in diabetic patients: increased risk of hyperkalemia and renal impairment. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - Lithium: can raise lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and impair renal function. - Thiazide diuretics: may enhance hypotensive effect; monitor blood pressure. - CYP2C9 inhibitors (e.g., fluconazole): can increase irbesartan plasma concentrations.